Literature DB >> 29526145

Observational prospective study on Lactobacillus plantarum P 17630 in the prevention of vaginal infections, during and after systemic antibiotic therapy or in women with recurrent vaginal or genitourinary infections.

Antonio Cianci1, Ettore Cicinelli2, Vincenzo De Leo3, Franca Fruzzetti4, Maria Giulia Massaro3, Alessandro Bulfoni5, Fabio Parazzini5, Antonio Perino6.   

Abstract

We performed a prospective cohort parallel observational study on the use of Lactobacillus plantarum P 17630 in the prevention of vaginal infections. Eligible were women with a diagnosis of bacterial vaginosis (<15 days) and documented history of recurrent vaginal infections; and/or cystitis (<15 days); and/or treatment with antibiotics for bacterial respiratory tract infections during the week before the study entry. Study subjects were prescribed Lactobacillus plantarum P 17630 > 100.000.000 UFC one vaginal capsule per day for 6 days, then a capsule per week for 16 weeks. Eligible subjects were enrolled in two parallel cohorts: 85 women using (group A) and 39 not using (group B) Lactobacillus plantarum P 17630. The risk of recurrent infection within 4 months from the study entry, was higher among untreated women: multivariate OR 2.6 (95%CI 0.7-9.4). The modification of presence/intensity or symptoms was significant in both the study groups (p < .001). Impact statement What is already known on this subject? The Lactobacillus plantarum P 17630 has been shown to be active in the treatment of bacterial vaginosis and vaginal candidiasis. No data are available on its efficacy in the prevention of recurrent vaginal or urological infection or as a prevention strategy during systemic treatment with antibiotics. What do the results of this study add? This observational study suggests that Lactobacillus plantarum given for 4 months may lower the risk of recurrent infection in women with recurrent vaginal or genitourinary infection or after antibiotic systemic treatment for bacterial respiratory tract infection. The finding, however, is not statistically significant, possibly due to the lower than expected rate of infection observed in our population and consequently the limited power of the study. What are the implications of these findings for clinical practice and/or further research? New studies are needed in order to evaluate in different populations the role of Lactobacillus plantarum in lowering the risk of recurrent infection in a high-risk populations.

Entities:  

Keywords:  Lactobacillus plantarum; Prevention; bacterial vaginosis

Mesh:

Substances:

Year:  2018        PMID: 29526145     DOI: 10.1080/01443615.2017.1399992

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  4 in total

1.  Interspecies Inhibition of Porphyromonas gingivalis by Yogurt-Derived Lactobacillus delbrueckii Requires Active Pyruvate Oxidase.

Authors:  Louis P Cornacchione; Brian A Klein; Margaret J Duncan; Linden T Hu
Journal:  Appl Environ Microbiol       Date:  2019-08-29       Impact factor: 4.792

2.  Prevention and treatment of cystitis during menopause: efficacy of a nutraceutical containing D-mannose, inulin, cranberry, bearberry, Olea europaea, Orthosiphon and Lactobacillus acidophilus.

Authors:  Giampaolo Mainini; Mario Passaro; Antonio Schiattarella; Pasquale De Franciscis; Mariano C Di Donna; Gennaro Trezza
Journal:  Prz Menopauzalny       Date:  2020-10-02

3.  Sucrose, maltodextrin and inulin efficacy as cryoprotectant, preservative and prebiotic - towards a freeze dried Lactobacillus plantarum topical probiotic.

Authors:  Sumbo Oluwatoyin Oluwatosin; Siew Leng Tai; Marijke Antonia Fagan-Endres
Journal:  Biotechnol Rep (Amst)       Date:  2021-12-24

4.  Probiotic Lacticaseibacillus rhamnosus GR-1 and Limosilactobacillus reuteri RC-14 as an Adjunctive Treatment for Bacterial Vaginosis Do Not Increase the Cure Rate in a Chinese Cohort: A Prospective, Parallel-Group, Randomized, Controlled Study.

Authors:  Yongke Zhang; Jinli Lyu; Lan Ge; Liting Huang; Zhuobing Peng; Yiheng Liang; Xiaowei Zhang; Shangrong Fan
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.